| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802099102010 | 209910201 | PROCEF F.C.TAB 500MG/TAB BTx8(BLISTER) | 5.80 | 06.08 | 8.37 |
| 05/2018 | 2802099102027 | 209910202 | PROCEF F.C.TAB 500MG/TAB BTx12(BLISTER) | 6.38 | 6.69 | 9.23 |
| 05/2018 | 2802099103017 | 209910301 | PROCEF PD.ORA.SUS 250MG/5ML FLX60ML | 5.76 | 06.04 | 8.32 |
| 05/2018 | 2802099103024 | 209910302 | PROCEF PD.ORA.SUS 250MG/5ML FL X 100 ML | 5.84 | 6.13 | 8.45 |
For the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefprozil interferes with an autolysin inhibitor.
Single 5000 mg/kg oral doses of cefprozil caused no mortality or signs of toxicity in adult, weaning or neonatal rats, or adult mice. A single oral dose of 3000 mg/kg caused diarrhea and loss of appetite in cynomolgus monkeys, but no mortality.
Oral bioavailability is approximately 95%.
1.3 hours
* 0.23 L/kg
* 3 mL/min/kg [fasting subjects]